Please assess the completion status of the following clinical trial:

Trial Title: Harm Reduction With Pharmacotherapy (HaRP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* being a registered client at one of the named partnering sites~* being at least 21 years of age (for legal reasons)~* agreeing to use an adequate form of birth control (if female and in childbearing years) fulfilling criteria for current alcohol dependence according to DSM-IV-TR criteria as determined by the SCID-I/P~Exclusion Criteria:~* refusal or inability to consent to participation in research~* constituting a risk to safety and security of other clients or staff~* known sensitivity or allergy to naltrexone/XR-NTX~* current treatment with naltrexone/XR-NTX~* being pregnant or nursing~* suicide attempts within the past year~* renal insufficiency/serum creatinine level \> 1.5~* current opioid dependence according to the DSM-IV-TR criteria~* liver transaminases (AST, ALT) \> 5 times the upper limit of normal (ULN)~* clinical diagnosis of decompensated liver disease

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Assessment-only (Type: NO_INTERVENTION): Assessment-only control condition
- HRC (Type: ACTIVE_COMPARATOR): Harm reduction counseling, which entails provision of feedback and support of harm reduction goals and safer drinking provided at one-month intervals over a 3-month period.
- XR-NTX+HRC (Type: EXPERIMENTAL): 3 doses of active medication (380 mg injection/month) + Harm reduction counseling at one-month intervals over three months.
- Placebo+HRC (Type: PLACEBO_COMPARATOR): 3 doses of placebo + harm reduction counseling at one-month intervals over a three-month period

Based on this trial design, predict the completion outcome and termination type (if applicable).